An Efficient Fabrication Approach for Multi-Cancer Responsive Chemoimmuno Co-Delivery Nanoparticles

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapy

Background:

• Cancer remains a leading cause of death, with significant contributions from breast, liver, and pancreatic cancers.
• Traditional cancer treatments suffer from dose-limiting toxicity, drug resistance, and limited efficacy.
• Co-delivery of chemotherapy and immunotherapy is challenging due to differing physicochemical properties of agents.

Purpose of the Study:

• To develop a novel chitosan-based nanoparticle system for the efficient co-delivery of paclitaxel (PTX) and polyinosinic-polycytidylic acid (Poly IC).
• To overcome the challenges of co-formulating hydrophobic PTX and hydrophilic Poly IC.
• To evaluate the therapeutic efficacy of the dual-modal delivery system in vitro.

Main Methods:

• Chitosan-PEG (CP) nanoparticles were synthesized to encapsulate both PTX and Poly IC.
• The physicochemical properties, cellular uptake, and stability of the nanoparticles were assessed.
• In vitro studies were conducted on breast (4T1), liver (HepG2), and pancreatic (Pan02) cancer cell lines.

Main Results:

• Chitosan-PEG nanoparticles exhibited an average size of approximately 100 nm, ensuring efficient cellular uptake and stability.
• CP-PTX-Poly IC nanoparticles significantly reduced the viability of breast, liver, and pancreatic cancer cells.
• The nanoparticles demonstrated enhanced dendritic cell (DC) maturation, indicating an improved immune response.

Conclusions:

• The developed dual-modal delivery system effectively combines chemotherapy and immunotherapy.
• Chitosan-based nanoparticles offer a promising platform for overcoming challenges in co-delivery of diverse therapeutic agents.
• This approach holds potential for more effective cancer treatment strategies and improved patient outcomes.